TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01295073
Drug: Trientine Hydrochloride
Normalized name: Trientine Hydrochloride
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery.
Study: NCT06540261
Drug: ONO-7913
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06540261
Drug: ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06540261
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06540261
Drug: Levofolinate
Normalized name: sodium levofolinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06540261
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06540261
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT04335721
Drug: Voxelotor
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Voxelotor 1500mg once a day
Study: NCT06504992
Drug: Vancomycin 1000 MG
Normalized name: vancomycin 1000 MG
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Powdered, intrawound vancomycin 1000 mg at the time of definitive surgery for open fracture fixation in addition to the current best practice of intravenous antibiotics with irrigation and debridement
Study: NCT05199337
Drug: ZN-d5
Normalized name: VITAMIN D5
DrugBank: 1alpha-Hydroxyvitamin D5 (DB13097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-d5 will be administered orally
Study: NCT04971746
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On Days 1 and 13, participants will receive an oral dose of pirfenidone.
Study: NCT04971746
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: On Days 1 and 13, participants will receive an oral dose of nintedanib.
Study: NCT04854174
Drug: ZN-d5
Normalized name: VITAMIN D5
DrugBank: 1alpha-Hydroxyvitamin D5 (DB13097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agent; 25 mg formulation
Study: NCT05636228
Drug: INV-102
Normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: INV-102 Ophthalmic Solution
Study: NCT05082610
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and programmed cell death ligand 2 (PD-L2).
Study: NCT06478186
Drug: triamcinolone acetonide extended-release injectable suspension; TCA-ER
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection
Study: NCT06478186
Drug: Triamcinolone Acetonide- Immediate Release;TCA-IR
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)
Study: NCT04977453
Drug: GI-101
Normalized name: GI-101
DrugBank: GI-101 (DB17243)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study: NCT04977453
Drug: Pembrolizumab (KEYTRUDA®)
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
Study: NCT04977453
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered at an approved dose orally.
Study: NCT04977453
Drug: GI-101A
Normalized name: camphor
DrugBank: GI-101 (DB17243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study: NCT06537700
Drug: OnabotulinumtoxinA OBT-A
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will be re-evaluated every 3 months, at each OBT-A cycle, during the whole year of treatment. Every evaluation patients will show their diary of headaches with monthly migraine and headache days and acute medications taken.
Study: NCT05546879
Drug: NP137
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NP137 at 9 or 14 mg/kg IV will be administered every 21 days.
Study: NCT05546879
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
Study: NCT05546879
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
Study: NCT05846659
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
Study: NCT05718024
Drug: Dexmedetomidine-esketamine
Normalized name: esketamine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
Study: NCT05283161
Drug: cannabidiol and tetrahydrocannabinol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD and THC will be given in the same concentration within a group of 10 participants, while its effects will be compared with the other two groups with 10 participants each and the placebo group.
Study: NCT05411705
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO 300U/kg/d QD, subcutaneous injection applied for 5 days per cycle, total 3 cycles. If the patient's platelet count showed a trend of continuous decline and/or was accompanied by the risk of bleeding during the treatment or after the completion of 5 doses of rhTPO, the investigator judged that rhTPO should be continued for treatment, and rhTPO could be administered subcutaneously at 300U/kg/ day for a maximum of 14 doses per cycle. Discontinue when the absolute platelet count increases by ≥50×10\^9/L or when the platelet count rises to ≥250×10\^9/L.
Study: NCT05411705
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-rhTPO treatment
Study: NCT06595017
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger points at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of magnesium sulphate
Study: NCT06595017
Drug: Lidocaine (drug)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Lidocaine
Study: NCT06595017
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After localization of the trigger points, the skin was disinfected with alcohol, the tight muscle band was grabbed between two fingers, and a 30-gage 3/4-inch needle was introduced 1-2 cm away from the trigger point at a 30º angle to the skin. Negative aspiration was performed and each trigger point was injected with 2 ml of Saline
Study: NCT06593717
Drug: Fluid bolus
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning.
Study: NCT05710848
Drug: STM-416
Normalized name: STM 217
DrugBank: STM-217 (DB17358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STM-416 monotherapy
Study: NCT06589817
Drug: Hydrochloride Carliprazine capsules
Normalized name: cariprazine hydrochloride
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Study: NCT06589817
Drug: Aripiprazole tablets
Normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration, once daily, with a total treatment duration of 6 weeks after successful screening.
Study: NCT04725864
Drug: Progesterone vaginal tablet
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study drug is progesterone 100 mg administrated as a vaginal tablet three times daily.
Study: NCT00002021
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05333549
Drug: Istradefylline medication
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
Study: NCT05946837
Drug: Indocyanine green (ICG) dye
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
Study: NCT06601036
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will undergo fiberoptic intubation under sevoflurane sedation.
Study: NCT06588699
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally once daily
Study: NCT04049539
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05677334
Drug: Henagliflozin
Normalized name: Henagliflozin
DrugBank: Henagliflozin (DB11939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion
Study: NCT05777031
Drug: Collagenase Clostridium Histolyticum (CCH)
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.
Study: NCT05663775
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA)
Study: NCT06515834
Drug: FE 999301
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To assess the safety and tolerability of FE 999301 after single intravenous (IV) dose infusion in healthy Japanese men
Study: NCT05602818
Drug: Soticlestat 300 mg
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05602818
Drug: Soticlestat 600 mg
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05602818
Drug: Soticlestat 900 mg
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05602818
Drug: Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06603142
Drug: Febuxostat 20MG Tablets
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 20MG Tablets
Study: NCT06603142
Drug: Febuxostat 20MG Placebo
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 20MG Placebo
Study: NCT06603142
Drug: Febuxostat 40MG Tablets
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 40MG Tablets
Study: NCT06603142
Drug: Febuxostat 40MG Placebo
Normalized name: febuxostat 40 MG
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 40MG Placebo
Study: NCT05006352
Drug: DNL343
Normalized name: DNL343
DrugBank: DNL343 (DB18678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT06590662
Drug: Solriamfetol
Normalized name: Solriamfetol
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient with a diagnostic of idiopathic hypersomnia (ICSD-3 criteria) will be randomized to receive solriamfetol or placebo for 7 weeks of treatment period. For the experimental arm, the dose will be progressively increased beginning at 75 mg to 300 mg according to tolerance to treatment.~Solriamfetol will be taken once a day upon awakening Schema of dispensation~1. One tablet of solriamfetol 75 mg per day for 1 week (week 1)~2. 150 mg of solriamfetol per day for 2 weeks (weeks 2 and 3)~3. According clinical judgment, Dose either maintained stable at 150 mg or increased to 300 mg per day for 2 weeks (weeks 4 and 5).~4. Prescription at week 5: Dose maintained at 150 or 300 mg or reduced at 150 mg per day according to benefit and safety for 2 weeks.~Treatment duration: 7 weeks treatment period.
Study: NCT06601309
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.
Study: NCT06601309
Drug: Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.
Study: NCT06601309
Drug: Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.
Study: NCT05766410
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4, 6 inhibitor
Study: NCT05766410
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CDK4, 6 inhibitor
Study: NCT05766410
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4, 6 inhibitor
Study: NCT05766410
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endocrine therapy
Study: NCT06212973
Drug: Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln
Normalized name: epinastine
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epinastine Hydrochloride Eye Drops + Simulating Azelastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
Study: NCT06212973
Drug: Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln
Normalized name: epinastine
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azelastine Hydrochloride Eye Drops + Simulating Epinastine Hydrochloride Eye Drops are used: both eyes are administered twice daily, once in the morning and once in the evening, with an interval of 8-12 hours between administrations; each time, 1 drop of each of the two eye drops is placed in each eye into the conjunctiva, and the two eye drops are applied at intervals of more than 5 minutes.
Study: NCT05087706
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400mg qd po
Study: NCT05087706
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide was administered orally at a daily dose of 50 mg
Study: NCT05087706
Drug: Leuprorelin
Normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
Study: NCT05102734
Drug: Nitroglycerin Topical Product
Normalized name: nitroglycerin Topical Product
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerin solution
Study: NCT06310876
Drug: ABBV-CLS-7262
Normalized name: ABBV-CLS-7262
DrugBank: ABBV-CLS-7262 (DB18407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: • single oral Dose 1
Study: NCT06310876
Drug: ABBV-CLS-7262
Normalized name: ABBV-CLS-7262
DrugBank: ABBV-CLS-7262 (DB18407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: • single oral Dose 2
Study: NCT06310876
Drug: Moxifloxacin 400mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • single oral dose
Study: NCT02875262
Drug: Deferoxamine
Normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
Study: NCT06191796
Drug: zanzalintinib
Normalized name: Zanzalintinib
DrugBank: Zanzalintinib (DB17525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified doses on specified days
Study: NCT06191796
Drug: AB521
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified doses on specified days
Study: NCT04794530
Drug: cocoa flavanols
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cocoa flavanols intervention is manufactured by Mars Inc. Participants randomized to cocoa flavanols will take two capsules daily of cocoa flavanols. The two capsules of cocoa flavanols will contain approximately 500 mg of cocoa flavanols and appoximately 80 mg of (-)-epicatechin.
Study: NCT05661643
Drug: Temozolomide capsule
Normalized name: Temozolomide Capsules
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
Study: NCT04596267
Drug: Pitolisant
Normalized name: pitolisant
DrugBank: Pitolisant (DB11642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 8.9mg Pitolisant for 5 days
Study: NCT06493864
Drug: BL-B16D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05421065
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 oral dose
Study: NCT05421065
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 oral dose
Study: NCT04820933
Drug: Doravirine 100 Mg
Normalized name: doravirine 100 MG
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doravirine 100 Mg orally dail
Study: NCT05005182
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04895423
Drug: Cyclosporine therapy
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine per os 3 mg/m2 2 times a day within 12 months
Study: NCT04895423
Drug: Dupilumab therapy
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients weighing \<30 kg received an initial dose of 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 4 weeks. Patients weighing 30 to \<60 kg received an initial dose of 400 mg (2 injections of 200 mg subcutaneously), then 200 mg every 2 weeks; Patients weighing 60 kg or more, the initial dose is 600 mg (2 injections of 300 mg subcutaneously), then 300 mg every 2 weeks.
Study: NCT05926804
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 days of Lansoprazole (30 mg BID) (days 1-14)
Study: NCT05926804
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days of Amoxicillin (1000 mg BID) (days 1-7)